Status:
UNKNOWN
Phenotypes, Biomarkers and Pathophysiology in Spastic Ataxias
Lead Sponsor:
Dr. Rebecca Schule
Collaborating Sponsors:
German Center for Neurodegenerative Diseases (DZNE)
German Research Foundation
Conditions:
Spastic Ataxia
Eligibility:
All Genders
Brief Summary
The aim of this study is to determine the clinical spectrum and natural progression of Spastic Ataxias (SPAX) and related disorders in a prospective multicenter natural history study, identify digital...
Detailed Description
The investigators will perform a registry-based standardized prospective Natural History Study (NHS) in SPAX and related disorders. Participants will be seen annually. At study visits a standardized c...
Eligibility Criteria
Inclusion
- ARSACS cohort: genetic diagnosis of ARSACS and clinically manifest disease
- SPG7 cohort: genetic diagnosis of SPG7 and clinically manifest disease
- Unrelated healthy controls: no signs or history of neurological or psychiatric disease
- AND
- written informed consent provided
- AND
- Participants are willing and able to comply with study procedures
Exclusion
- Missing informed consent
- For controls: evidence of a neurodegenerative disease or movement disorders; inability to give informed consent
Key Trial Info
Start Date :
September 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04297891
Start Date
September 1 2020
End Date
June 1 2025
Last Update
May 18 2022
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Montreal Neurological Institute of McGill University, Department of Neurology and Neurosurgery and Human Genetics
Montreal, Quebec, Canada, H3A 2B4
2
Université de Sherbrooke
Saguenay, Quebec, Canada, G7X 7X2
3
Département d'information médicale (DIM); Département de Biostatistique, Santn 3emé Publique et Information Médicale (BIOSPIM)- Bâtiment Mazarie étage; Hôpitaux Universitaires Pitié Salpêtrière
Paris, France, 75013
4
Center for Neurology & Hertie-Institute for Clinical Brain Research, Dept. for Neurodegenerative Diseases
Tübingen, Baden-Wurttemberg, Germany, 72076